News summary

New Diranersen Data at CTAD Mark Continued Progress Toward Combination Therapies for Alzheimer

Source: PR Newswire • Published: 18 Nov 2026, 16:36

Summarized by Masters of Longevity from PR Newswire.

Two-year data suggest diranersen slowed cognitive decline in early Alzheimer's.

New Diranersen Data at CTAD Mark Continued Progress Toward Combination Therapies for Alzheimer
Key Takeaways
  • Two-year CELIA data showed a greater slowing of cognitive decline.
  • The lowest dose was reported to have the best balance of benefit.
  • Diranersen reduced tau while leaving amyloid measures largely unchanged.
Read the full article at PR Newswire ↗

Continue exploring

Recommended MoL Picks

MoL PickLongevity is leaving the clinicStephen Watson argues that hotels, gyms and residential communities can build longevity memberships around the relationships they already have.MoL PickCan Exergaming Improve Balance? What Older Adults Should KnowMotion-controlled games may make balance practice easier to repeat. The evidence supports a structured adjunct—not a fall-proofing shortcut.MoL PickWhat Changes in the Human Hippocampus with Age?A study of 40 postmortem brains maps a midlife shift in immune cells and a wider loss of cellular and genome organisation—but it does not show how to prevent cognitive decline.